Liquidia Revenue Growth Rates (LQDA), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Liquidia Corporation  (NASDAQ: LQDA)
 

LQDA's Revenue Growth by Quarter and Year

Liquidia's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/LQDA/growth
https://api.csimarket.com/api/v1/companies/LQDA/fundamentals
https://api.csimarket.com/api/v1/companies/LQDA/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
LQDA Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 225.30
2nd Quarter June 171.68
1st Quarter March 132.87
FY 529.85

LQDAs Annual Revenue
Liquidia's Revenue in the fiscal year 2025 $ 158.32 millions
Liquidia's Revenue in the fiscal year 2024 $ 14.00 millions
Liquidia's Revenue in the fiscal year 2023 $ 17.49 millions
Liquidia's Revenue in the fiscal year 2022 $ 15.94 millions
Liquidia's Revenue in the fiscal year 2021 $ 12.85 millions




LQDA Revenue third quarter 2026 Y/Y Growth Comment
Liquidia Corporation reported Revenue surge of 314.61% year on year in the third quarter 2026, to $ 225.30 millions, this is lower than Liquidia Corporation's recent average Revenue surge of 353.92%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 57 other companies have achieved higher Revenue growth. While Liquidia Corporation' s Revenue doubling of 314.61% ranks overall at the positon no. 463 in the third quarter 2026.


LQDA Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 314.61 %
2nd Quarter June 1842.08 %
1st Quarter March 4158.65 %
FY   -

Financial Statements
Liquidia's third quarter 2026 Revenue $ 225.30 millions LQDA's Income Statement
Liquidia's third quarter 2025 Revenue $ 54.34 millions Quarterly LQDA's Income Statement


LQDA Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 31.23 %
2nd Quarter June 29.21 %
1st Quarter March 44.39 %
FY (Year on Year)   -


Back to LQDA Growth rate Comparisons >> Back to LQDA Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #463

Revenue Y/Y Growth Statistics
High Average Low
2233.65 % 353.92 % -19.97 %
(Jun 30 2026)   (Dec 31 2024)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #58
Healthcare Sector #114
Overall #463
Revenue Y/Y Growth Statistics
High Average Low
2233.65 % 353.92 % -19.97 %
(Jun 30 2026)   (Dec 31 2024)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Liquidia's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
514.94 % 39.31 % -100 %
(Sep 30 2025)  


LQDA's III. Quarter Q/Q Revenue Comment
Liquidia Corporation achieved in the III. Quarter 2026 below company average Revenue jump of 31.23% quarter on quarter, to $ 225.30 millions.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Liquidia's Revenue growth quarter on quarter, overall rank is 378.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #378
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #41
Healthcare Sector #84
Overall #378
Revenue Q/Q Growth Statistics
High Average Low
514.94 % 39.31 % -100 %
(Sep 30 2025)  


LQDA's III. Quarter Q/Q Revenue Comment
Liquidia Corporation achieved in the III. Quarter 2026 below company average Revenue jump of 31.23% quarter on quarter, to $ 225.30 millions.

Within Major Pharmaceutical Preparations industry 40 other companies have achieved higher Revenue quarter on quarter growth. While Liquidia's Revenue growth quarter on quarter, overall rank is 378.


Liquidia's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 621.87
Y / Y Revenue Growth (TTM) 798.44 %
Year on Year Revenue Growth Overall Ranking # 559
Seqeuential Revenue Change (TTM) 37.91 %
Seq. Revenue Growth (TTM) Overall Ranking # 463


Cumulative Revenue growth Comment
Assuming the Liquidia's fiscal year would have ended in Sep 30 2026, Liquidia would have reprted above average annual Revenue surge of 798.44% year on year, of $ 622 millions.
This marks a slow-down of the companys growth trends and from the 2233.65% surge in Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 559, from total ranking in previous quarter at 2299.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
2233.65 %
 353.92 %
-19.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 114
S&P 500 # 463
Cumulative Revenue growth Comment
Assuming the Liquidia's fiscal year would have ended in Sep 30 2026, Liquidia would have reprted above average annual Revenue surge of 798.44% year on year, of $ 622 millions.
This marks a slow-down of the companys growth trends and from the 2233.65% surge in Jun 30 2026.

In the Healthcare sector 126 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 559, from total ranking in previous quarter at 2299.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 58
Healthcare Sector # 127
Overall # 559

Revenue TTM Y/Y Growth Statistics
High Average Low
2233.65 %
353.92 %
-19.97 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 58
Sector # 114
S&P 500 # 463




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
LQDA's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue surge for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Bio Green Med Solution Inc 460.49%$ 460.494 millions
Xencor Inc454.88%$ 454.884 millions
Tonix Pharmaceuticals Holding Corp 423.83%$ 423.830 millions
Nakamoto Inc 396.90%$ 396.897 millions
EBR Systems, Inc.385.65%$ 385.647 millions
Solana Company382.07%$ 382.066 millions
Pulse Biosciences Inc 359.30%$ 359.302 millions
Ensysce Biosciences Inc 342.43%$ 342.428 millions
Nexalin Technology Inc 331.43%$ 331.434 millions
Agios Pharmaceuticals Inc 330.01%$ 330.008 millions
Insmed Inc330.00%$ 330.000 millions
Monte Rosa Therapeutics Inc 325.80%$ 325.799 millions
Liquidia Corporation314.60%$ 314.596 millions
Stablecoin Development Corporation310.75%$ 310.749 millions
Renovorx Inc 300.75%$ 300.752 millions
Aligos Therapeutics Inc 281.92%$ 281.916 millions
Clene Inc 273.33%$ 273.333 millions
Recursion Pharmaceuticals Inc 258.49%$ 258.493 millions
Nuvation Bio Inc 251.98%$ 251.977 millions
Seastar Medical Holding Corp246.99%$ 246.995 millions
Prime Medicine Inc 243.92%$ 243.918 millions
Urogen Pharma Ltd 227.16%$ 227.161 millions
Dianthus Therapeutics Inc 205.56%$ 205.556 millions
Bridgebio Pharma Inc 192.60%$ 192.602 millions
Bicycle Therapeutics Plc190.24%$ 190.242 millions
Gossamer Bio Inc 189.09%$ 189.085 millions
Alpha Cognition Inc.173.75%$ 173.751 millions
Eton Pharmaceuticals Inc 165.04%$ 165.042 millions
Sera Prognostics Inc 162.50%$ 162.500 millions


About Liquidia Revenue Growth Rates (LQDA), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.